PharmaFocus Today – Page 13 – media

Crizotinol Ointment Approved for Market Launch; Jiudian Topical Products Expands to New Indications

Recently, Jiudian Pharmaceutical’s Crizotinol Ointment officially received registration approval from the National Medical Products Administration, which is considered equivalent to passing the generic drug consistency evaluation. This product is a Class B drug covered by the National Medical Insurance Program and is suitable for the topical treatment of mild to moderate atopic dermatitis in children aged 3 months and older and adults. This approval marks a new breakthrough for Jiudian Pharmaceutical in the field of topical medications, further expanding the therapeutic indications of its topical product portfolio from the anti-inflammatory and analgesic field to the field of skin immune inflammation regulation. Atopic dermatitis is a chronic, relapsing, inflammatory skin disease, and its prevalence among children in my country is showing an increasing trend year by year. For a long time, topical treatment for mild to moderate atopic dermatitis has mainly relied on corticosteroids and calcineurin inhibitors. However, long-term use of ...
- Source: drugdu
- 105
- May 8, 2026
Shanghai Pharmaceuticals’ Rivaroxaban Tablets Receive Thai Drug Registration Certificate

Recently, rivaroxaban tablets produced by Changzhou Pharmaceutical Factory Co., Ltd., a subsidiary of Shanghai Pharmaceuticals, received a drug registration certificate issued by the Thai Food and Drug Administration, and the drug has been approved for marketing. Rivaroxaban tablets are primarily used to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation; to treat and prevent deep vein thrombosis (DVT); to treat pulmonary embolism (PE); and to prevent venous thromboembolism (VTE) in patients with acute illness. Rivaroxaban tablets were originally developed jointly by Bayer and Janssen and were launched in the United States in 2011. In May 2025, Changzhou Pharmaceutical Factory’s rivaroxaban tablets obtained approval from the U.S. Food and Drug Administration. In October 2025, it obtained a drug registration certificate in Malaysia, and in February 2026, it obtained a drug registration certificate in Singapore. According to IQVIA database, the total sales of rivaroxaban tablets in ...
- Source: drugdu
- 111
- May 8, 2026
The world’s first biased GLP-1RA officially enters commercialization.

Today, the world’s first approved cAMP-biased GLP-1 receptor agonist, enoglutide injection (Xianweiying® ) , was simultaneously issued as the first batch of prescriptions nationwide at Peking University People’s Hospital and Zhongshan Hospital affiliated with Fudan University, marking the official entry of this innovative weight management therapy into the clinical application stage in China. Currently, there are two routes for the innovative development of GLP-1 receptor agonists. The traditional route uses GLP-1 as the core target, combined with other targets such as GIP and GCG. The biased signaling mechanism of enoglutin originates from the Nobel Prize-winning research on the structure and function of G protein-coupled receptors (GPCRs). The clinical use of enoglutin reflects a shift in weight management clinical practice from simply focusing on the rate of weight loss to a comprehensive consideration of tolerability, sustainability, and the overall patient experience. Addressing the Challenges of Long-Term Weight Management In recent years, ...
- Source: drugdu
- 144
- April 28, 2026
Breaking News! BeiGene Introduces a PD-1/VEGF Triple Antibody

On April 27, Huahui Anjian announced that it had entered into a global exclusive option, licensing and collaboration agreement with BeiGene for the novel tumor immunotherapy trispecific antibody HH160 , granting BeiGene an exclusive option involving the development, production and commercialization of the product. Under the agreement, BeiGene will pay Huahui Anjian an upfront payment of US$20 million. Huahui Anjian is entitled to an additional US$100 million exercise payment if BeiGene exercises its option. Upon achieving development and regulatory milestones, Huahui Anjian is entitled to payments of up to US$374 million. Upon achieving sales milestones, Huahui Anjian is entitled to payments of up to US$1.53 billion, and is also entitled to tiered licensing fees. In addition, both parties will actively negotiate and discuss BeiGene’s potential participation in Huahui Anjian’s financing, and the specific transaction terms and details will be determined through further negotiation. HH160 is a novel trispecific antibody developed ...
- Source: drugdu
- 144
- April 28, 2026
AstraZeneca’s dual immunotherapy has been approved for marketing in China for a new indication

AstraZeneca recently announced that the China National Medical Products Administration (NMPA) has officially approved durvalumab (trade name: Imfinzi® ) in combination with tramapimab (trade name: Imfinzi® ) for first-line treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC). In addition, durvalumab has also been approved as monotherapy for first-line treatment of adult patients with advanced or unresectable HCC. According to the “Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2026 Edition),” the number of new cases of primary liver cancer in China in 2022 was 367,700, accounting for 42.5% of global cases; the number of deaths from primary liver cancer in 2022 was 316,500, ranking second in both the number of deaths and the case fatality rate; the 5-year relative survival rate of liver cancer in the Chinese population was 14.4%, and the proportion of patients diagnosed at intermediate or advanced stages reached more than 50%. ...
- Source: drugdu
- 151
- April 28, 2026
A market worth hundreds of billions! Where is the next trump card in the cosmetic injection industry?

Driven by compliance reforms and stricter regulations, the medical aesthetics device industry is poised for a landmark transformation, with the overall market experiencing a dual surge driven by both consumer upgrades and technological advancements. The market size for injectable medical aesthetics products is projected to grow from 67 billion yuan in 2023 to 147 billion yuan in 2027, maintaining a high compound annual growth rate. However, within this multi-billion yuan market, the four main materials exhibit distinct competitive landscapes. This report, compiled by Yaozhi Medical Device Data based on data from multiple sources, systematically describes the size, growth rate, and structural evolution of the medical aesthetic injection product market, the competitive landscape of the four major materials, demand changes, and behavioral analysis. It aims to provide industry participants with data insights and trend analysis to assist in strategic decision-making and resource optimization. 01 Product Overview Injectable cosmetic products primarily achieve ...
- Source: drugdu
- 137
- April 28, 2026
Thirteen Class 1 new drugs have been approved for clinical trials! Innovent, Hansoh, Gan & Lee, and Health-One, among others, have entered the fray

In the past week, China has seen a number of new developments in clinical trial applications for innovative drugs . Data shows that from April 20th to April 26th, 2026, 13 Class 1 new drugs were approved for clinical trials, linked to 19 application numbers. These drugs cover chemical drugs, therapeutic biological products, and traditional Chinese medicine, involving multiple areas such as ADCs, bispecific antibodies, siRNA, small molecule inhibitors, anti-infective drugs, and innovative traditional Chinese medicines. This batch of products includes projects from companies such as Innovent Biologics, Hansoh Pharmaceutical, Gan & Lee Pharmaceuticals, Health-One, and Qilu Pharmaceutical, as well as new developments in innovative traditional Chinese medicine and anti-infective drugs. More noteworthy than the approval of individual products for clinical trials is the simultaneous advancement of different technological approaches to the clinical stage. Antibody drugs remained one of the most active areas last week. Last week, therapeutic biologics projects ...
- Source: drugdu
- 112
- April 28, 2026
MicroWisdom Bio Completes Nearly RMB 100 Million B+ Round Supplementary Financing, Accelerating Bioartificial Liver Clinical Development and Industrialization

Arterial Network has learned that Shanghai MicroWisdom BioTech Co., Ltd. (hereinafter referred to as “MicroWisdom Bio”), an innovative biomedical enterprise focused on liver disease cell therapy and regenerative medicine, has recently successfully completed nearly RMB 100 million in B+ round supplementary financing. This supplementary round was jointly participated by Fullway Capital, Guangdong Technology Finance Group, Shum Yip Capital, Cuihung Innovation, and Zhongshan Venture Capital. The funds will be primarily used for the clinical development, process optimization, and subsequent pipeline development of the core product HepaCure bioartificial liver, further consolidating the company’s global leading position in the field of liver disease treatment. End-stage liver diseases such as liver failure represent a significant unmet clinical need, and bioartificial livers, as the most promising treatment modality, have become an industry focus. MicroWisdom Bio has been deeply engaged in this track for many years. Leveraging the internationally leading hepatocyte-like cell transdifferentiation technology (hiHep technology), ...
- Source: drugdu
- 126
- April 27, 2026
【Exclusive】Cenglang BioTech Secures Tens of Millions in Financing, Strengthens Domestic Core Competitiveness, Accelerates Global Strategy

Recently, Beijing Cenglang BioTech Co., Ltd. (hereinafter referred to as “Cenglang BioTech”), a well-known enterprise in China’s flow cytometry field, announced the completion of tens of millions of yuan in financing. This round was exclusively invested by Sunshine Harmony Capital, with StarBridge Capital serving as the exclusive financial advisor. Following its financing in March 2024, Cenglang BioTech has once again gained favor from the capital market, highlighting the industry’s broad recognition of domestic high-end flow cytometry technology innovation capabilities and commercialization prospects. Industry Breakthrough: Domestic Substitution of High-End Flow Cytometry is Imperative The U.S. Department of Commerce’s “High-Parameter Flow Cytometry Export Ban,” effective January 16, 2025, has caused significant shockwaves throughout the flow cytometry industry. The ban prohibits the export to China of flow cytometry products with “26 channels or more,” “full spectrum,” and “sorting-type” specifications. This has had a considerable impact on the development of life sciences in China, ...
- Source: drugdu
- 116
- April 27, 2026
Largest Ever! India’s Sun Pharma to Acquire Organon for $11.75 Billion in All-Cash Deal, Reshaping the Global Pharmaceutical Landscape

On April 27 (today), Sun Pharmaceutical Industries Limited (together with its subsidiaries and associates, collectively referred to as “Sun Pharma” hereinafter) and Organon & Co. (“Organon” hereinafter) jointly announced the signing of a definitive acquisition agreement. Under the terms of the agreement, Sun Pharma will acquire all outstanding shares of Organon in an all-cash transaction at a price of $14.00 per share, valuing the target company at $11.75 billion. As a global healthcare enterprise, Organon was spun off from Merck & Co. as an independent company in 2021. As a global leader in women’s health, Organon boasts solid brand credibility and strong brand assets. It offers over 70 products spanning two core segments: women’s health and general medicines, with business presence across 140 countries and a robust global footprint supported by six manufacturing sites. Upholding its founding mission in core operations, the company strives to improve access to medicines and ...
- Source: drugdu
- 123
- April 27, 2026

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.